Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Inventisbio LLC has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and 2 distinct art units. CHANDRAKUMAR, NIZAL S is the busiest examiner for the company, currently responsible for 1 pending action. This indicates that the company's current pharmaceutical prosecution is divided between two different examiners and units, ensuring that each case is reviewed independently.
With 2 pending office actions, the company must manage two separate prosecution timelines. The involvement of 2 distinct examiners means that the strategy for one action may not be applicable to the other, as each examiner will have their own interpretation of the Biotechnology & Pharmaceuticals prior art. CHANDRAKUMAR, NIZAL S and the other examiner will each apply the standards of their respective 2 distinct art units. For the practitioner, this requires a dual-focused approach that addresses the unique technical and procedural concerns of both examiners. This distribution of 2 pending office actions across 2 distinct examiners prevents a single individual from having a disproportionate impact on the company's current patent efforts in the pharmaceutical sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
| HERNANDEZ, JACKSON J | 1 | 50.7% | +39.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042872 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | HERNANDEZ, JACKSON J | 42d |
| 18578677 | PYRIDAZINONE OR PYRIDINONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | RAO, PADMAJA S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042872 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | HERNANDEZ, JACKSON J | 42d |
| 18578677 | PYRIDAZINONE OR PYRIDINONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | RAO, PADMAJA S | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18578677 | PYRIDAZINONE OR PYRIDINONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | RAO, PADMAJA S | 1627 | §102§112 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18042872 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | HERNANDEZ, JACKSON J | 1627 | §103§112 | Non-Final OA | 42d | Pending | Feb 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInventisbio LLC has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Padmaja S Rao has the most, with 1 of Inventisbio LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
